Corcept CFO exercises options, sells 40K shares
Corcept Therapeutics’ Chief Financial Officer Atabak Mokari reported option exercises and related share sales in the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Corcept Therapeutics’ Chief Financial Officer Atabak Mokari reported option exercises and related share sales in the company’s common stock. He exercised stock options covering 40,000 shares at an exercise price of $19.26 per share, then sold 40,000 shares in multiple open-market transactions at weighted average prices between approximately $79.40 and $82.18 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 16,130 common shares, which include shares underlying several unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.
Insider Trade Summary 10b5-1
Exercise and Sale: 40,000 shares ($2.48M approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Mokari Atabak
Role
Chief Financial Officer
Sold
40,000 shs ($3.25M)
Approx. gross sale proceeds
$3.25M
Approx. exercise cost
$770K
Approx. pre-tax spread
$2.48M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 40,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 40,000 | $19.26 | $770K |
| Sale | Common Stock | 9,434 | $80.0216 | $755K |
| Sale | Common Stock | 11,081 | $80.9424 | $897K |
| Sale | Common Stock | 19,483 | $81.8092 | $1.59M |
| Sale | Common Stock | 2 | $82.45 | $164.90 |
Holdings After Transaction:
Stock option (right to buy) — 20,000 contracts (Direct);
Common Stock — 16,130 shares (Direct)
Footnotes (6)
- F1. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $80.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.40 to $81.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.40 to $82.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F6. Fully exercisable.
Key Figures
Shares sold: 40,000 shares
Option exercise shares: 40,000 shares
Exercise price: $19.26 per share
+5 more
8 metrics
Shares sold
40,000 shares
Total common shares sold in open-market transactions on June 15, 2026
Option exercise shares
40,000 shares
Common shares acquired via stock option exercise on June 15, 2026
Exercise price
$19.26 per share
Strike price of stock options exercised for 40,000 shares
Post-transaction holdings
16,130 shares
Direct common stock owned by CFO after reported transactions
Highest weighted average sale price
$82.45 per share
Weighted average price for one sale tranche of 2 shares
Lowest price range bound
$79.40 per share
Lowest individual sale price in disclosed trade ranges
Highest price range bound
$82.18 per share
Highest individual sale price in disclosed trade ranges
Remaining options after exercise
20,000 options
Stock options still held after exercising 40,000, as reported
Key Terms
Rule 10b5-1 plan, restricted stock awards, stock option (right to buy), derivative security, +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person..."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock awards financial
"Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person..."
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
stock option (right to buy) financial
"security_title: "Stock option (right to buy)" with underlying security title Common Stock"
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Corcept Therapeutics (CORT) CFO Atabak Mokari report?
Corcept Therapeutics CFO Atabak Mokari reported exercising stock options for 40,000 common shares at $19.26 per share and selling 40,000 shares in multiple open-market transactions at weighted average prices between about $79.40 and $82.18, under a pre-arranged Rule 10b5-1 plan.
What stock option activity did the Corcept Therapeutics (CORT) CFO report?
The Form 4 shows the CFO exercised stock options covering 40,000 shares of common stock at an exercise price of $19.26 per share. A related derivative entry notes these options are now fully exercisable and had an original expiration date in 2032 before exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
